Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

Galapagos Appoints David Smith as CEO of Service Division

Published: Wednesday, August 21, 2013
Last Updated: Wednesday, August 21, 2013
Bookmark and Share
David Smith was CFO of Galapagos for two years.

Galapagos NV has announced the appointment of David Smith as CEO of the service division and member of the Galapagos Executive Committee.

Galapagos' service division comprises BioFocus and Argenta. Together with Fidelta, Galapagos has three leaders in premium drug discovery services for pharma, biotech, universities, and patient foundations.

Galapagos' service division and Fidelta meet clients' needs for drug discovery tools and expertise by providing a full range of services, from target discovery through to delivery of pre-clinical candidates, including compound libraries, medicinal chemistry and ADME/PK services.

To further optimize the performance and ensure further growth of this division and Fidelta, a CEO position has been created, to be filled by David Smith.

Chris Newton, John Montana and Phil Dudfield will lead BioFocus, Argenta, and Fidelta, respectively, as Managing Director; they will report to David Smith.

David will become member of the Galapagos Executive Committee and report to Galapagos CEO Onno van de Stolpe.

David Smith joins Galapagos from the Cambridge University Hospitals where he was Director Finance for six years. Previously he was CFO of Galapagos for two years, during which he played a key role in several M&A projects to build the service division between 2005 and 2007.

Prior to that, at AstraZeneca he held Marketing Company CFO roles (where he was also a Board member of the AstraZeneca Dutch Holdings Group) and a number of strategic and integration functions within R&D; at Coopers & Lybrand (now PriceWaterhouseCoopers) he was audit manager to a variety of industries and international clients in Dubai, and post qualification as a Chartered Accountant in Leeds he ran a number of companies in administration. David holds a degree in Molecular Biophysics from the University of Leeds.

"We welcome David back to Galapagos," said Onno van de Stolpe, Chief Executive Officer, Galapagos. "David brings valuable strategic and operational experience to the Galapagos Group, and he is already familiar with the services business from his previous role at the Company. We have confidence that he can take the successful Service division to the next level."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Galapagos Starts Phase 2A Study with GLPG0974 in Ulcerative Colitis
Study will deliver topline results early 2014.
Tuesday, April 23, 2013
Galapagos Discovers Novel Candidate Drug to Treat Breast Cancer
GLPG1790 has high efficacy against triple-negative breast cancer.
Monday, April 22, 2013
Galapagos Acquires Cangenix
Galapagos to add structure-based drug discovery to the Argenta service offering.
Wednesday, January 16, 2013
BioFocus and Ono Sign a Drug Discovery Agreement in the Field of CNS Disorders
BioFocus will use its drug discovery platform to deliver leads and clinical candidates for its client.
Monday, October 08, 2012
Ono and Galapagos Sign an Additional Target Discovery Agreement
Collaboration agreement on discovering novel targets in the field of allergic diseases.
Wednesday, May 30, 2012
Galapagos Delivers Candidate Drug in GSK Alliance
Galapagos NV has announced that it delivered a fourth candidate drug in its arthritis alliance with GlaxoSmithKline (GSK) in December 2010. This achievement triggered a €6.7 million milestone payment to Galapagos, which was included in 2010 revenues.
Friday, March 04, 2011
Galapagos Receives €2.7 Million Grant for Antiviral Drug Discovery
The antiviral programs focus on blocking the activity of a protein in the human body that is essential for a number of important pathogenic viruses to carry out their own reproduction.
Friday, February 18, 2011
Galapagos Receives €4 Million in Milestones from Servier
Servier and Galapagos announced their alliance to develop new medicines for the treatment of osteoarthritis.
Friday, February 18, 2011
Galapagos Receives €7.4 M Milestone in Arthritis Alliance with GlaxoSmithKline
Galapagos completed first-in-human trials for GLPG0555 and initiates clinical Phase I development for a second candidate drug, GLPG0778.
Thursday, January 13, 2011
Galapagos Receives €3.7 Million Grant for Cystic Fibrosis Program
The three-year project focuses on Galapagos' cystic fibrosis program based on novel drug targets to deliver a pre-clinical candidate.
Monday, November 01, 2010
Galapagos' Affiliate BioFocus Extends Collaboration with Chiesi
BioFocus to provide medicinal chemistry and biology services, with an additional option for ADME services, for a Chiesi therapeutic program.
Thursday, October 14, 2010
Galapagos' Affiliate Argenta and Janssen Enter in Integrated Cancer Drug Discovery Service Agreement
Initial phase includes research funding and success-based milestones over five years.
Saturday, October 09, 2010
Galapagos Initiates Phase I Study for JAK inhibitor GLPG0634
Company announces the acquisition of full rights to the compound from GSK.
Monday, August 09, 2010
Galapagos and University of Bristol Enter Drug Discovery Collaboration in Chronic Pain
BioFocus will provide hit-to-lead and lead optimization services for a €3.3 million drug discovery program at the University of Bristol.
Friday, July 16, 2010
NIH Extends Agreement with Galapagos Until End 2012
Galapagos will be eligible to receive up to $8.6 million over the course of the two year extension.
Monday, July 12, 2010
Scientific News
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Fighting Pain with Ketamine
Researchers at the Texas A&M Health Science Center are using ketamine, a drug that already exists as an anesthetic, to treat pain.
Possible New Treatment for Neurodegenerative Diseases Found
Researchers at the University of Liverpool have found that a well-established anti-epileptic drug could also be used as a treatment for neurodegenerative diseases.
Breast Cancer Drug Beats Superbug
Tamoxifen helps white blood cells clear multidrug-resistant bacteria in lab and mouse studies.
Have Your Drug Nano-Delivered Via Microbubble
A UC engineering professor is working to develop effective nanoparticle-bubble drug delivery systems to access precise locations in the body to treat medical conditions such as cancer, eye disease and spinal disc degeneration.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos